Indoco Counts On Indian Market Bouncing Back
Company Plans To Ramp Up Its Partnership With Teva By FY22
Executive Summary
Indoco’s domestic performance picks up pace as the Indian pharma market sees a “bounce back” after a long COVID-induced slump. The Indian company continues to perform well internationally and grow overall.